Trulicity Takes Hit From Payer Mix, But Lilly Emerges From Q3 Ahead
COVID-19 Antibody Bamlanivimab Fails In Sicker Patients
US pricing for Trulicity due to payer mix fluctuations dragged down solid volume growth. Lilly hopes revenue from COVID-19 therapies will help it hit annual guidance, but bamlanivimab failed to benefit hospitalized patients.
You may also be interested in...
It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Weeks after FDA authorized emergency use of its antibody bamlanivimab, Lilly’s RA drug Olumiant can be used to shorten recovery time for hospitalized COVID-19 patients in the US. Authorizations are being pursued elsewhere as well.